JO3680B1 - تركيبات صيدلانية موضعية - Google Patents

تركيبات صيدلانية موضعية

Info

Publication number
JO3680B1
JO3680B1 JOP/2016/0097A JOP20160097A JO3680B1 JO 3680 B1 JO3680 B1 JO 3680B1 JO P20160097 A JOP20160097 A JO P20160097A JO 3680 B1 JO3680 B1 JO 3680B1
Authority
JO
Jordan
Prior art keywords
topical pharmaceutical
skin
pharmaceutical compositions
patient
relates
Prior art date
Application number
JOP/2016/0097A
Other languages
English (en)
Inventor
Roger Thomas Joey
D Lenn Jon
E Whiteman Justin
L Santos Leandro
D Sonti Sujatha
Quinn Doherty Michael
Bedard Mary
Jain Piyush
Original Assignee
Dermavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56081527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3680(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dermavant Sciences GmbH filed Critical Dermavant Sciences GmbH
Application granted granted Critical
Publication of JO3680B1 publication Critical patent/JO3680B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبات مستحلبة صيدلانية موضعية تتضمن كمية فعالة علاجياً من 3، 5- ثاني هيدروكسي-4- أيزوبروبيل-ترانس- ستيلبين أو ملح مقبول صيدلانيا منه، طور زيتي، طور مائي، منشط للسطح، ومضاد للأكسدة، وفيها التركيب المستحلب عبارة عن مستحلب متجانس أو نشط والذي يذاب في طور الزيت. ويتعلق الاختراع أيضاً بطرق لعلاج حالات جلدية أو اضطراب الجلد في مريض بإعطاء التركيبات الحالية إلى جلد المريض
JOP/2016/0097A 2015-05-21 2016-05-19 تركيبات صيدلانية موضعية JO3680B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562165097P 2015-05-21 2015-05-21
US201662324450P 2016-04-19 2016-04-19

Publications (1)

Publication Number Publication Date
JO3680B1 true JO3680B1 (ar) 2020-08-27

Family

ID=56081527

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0097A JO3680B1 (ar) 2015-05-21 2016-05-19 تركيبات صيدلانية موضعية

Country Status (35)

Country Link
US (5) US10195160B2 (ar)
EP (2) EP4094752A1 (ar)
JP (4) JP6863904B2 (ar)
KR (2) KR102669247B1 (ar)
CN (2) CN114042041B (ar)
AU (2) AU2016263161B2 (ar)
BR (1) BR112017024934A8 (ar)
CA (1) CA2986251A1 (ar)
CL (1) CL2017002939A1 (ar)
CO (1) CO2017011795A2 (ar)
CR (1) CR20170528A (ar)
CY (1) CY1125318T1 (ar)
DK (1) DK3297605T3 (ar)
DO (1) DOP2017000270A (ar)
EA (1) EA038624B1 (ar)
ES (1) ES2914112T3 (ar)
HR (1) HRP20220670T1 (ar)
HU (1) HUE059066T2 (ar)
IL (3) IL282304B2 (ar)
JO (1) JO3680B1 (ar)
LT (1) LT3297605T (ar)
MX (2) MX377629B (ar)
PE (1) PE20180038A1 (ar)
PH (1) PH12017502092A1 (ar)
PL (1) PL3297605T3 (ar)
PT (1) PT3297605T (ar)
RS (1) RS63402B1 (ar)
SG (1) SG11201708666RA (ar)
SI (1) SI3297605T1 (ar)
SM (1) SMT202200224T1 (ar)
TW (1) TWI705831B (ar)
UA (1) UA125500C2 (ar)
UY (1) UY36682A (ar)
WO (1) WO2016185428A1 (ar)
ZA (1) ZA202007965B (ar)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11617724B2 (en) * 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
PL3297605T3 (pl) 2015-05-21 2022-07-11 Dermavant Sciences GmbH Kompozycje farmaceutyczne do stosowania miejscowego
CA3253169A1 (en) 2017-11-10 2025-10-27 Dermavant Sciences GmbH Process for preparing tapinarof
CN109085257B (zh) * 2018-07-05 2021-04-06 中央民族大学 一种同时定量检测小鼠血浆中黄芪甲苷-iv、环黄芪醇的方法
MX368750B (es) * 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
JP6898622B2 (ja) * 2019-01-30 2021-07-07 学校法人神奈川大学 皮膚又は粘膜の外用剤及びその製造方法、並びに皮膚又は粘膜の外用剤の基剤
KR20230110821A (ko) 2019-04-17 2023-07-25 아조라 테라퓨틱스 인코포레이티드 염증성 피부 질환을 치료하기 위한 국소 조성물 및방법
MX2021012874A (es) * 2019-05-15 2021-11-17 Leo Pharma As Tratamiento del lupus eritematoso cutaneo.
US20200383887A1 (en) * 2019-06-04 2020-12-10 L'oreal Oxygenate skin treatment system
BR112021026532A2 (pt) 2019-06-26 2022-05-24 Locus Oil Ip Company Llc Composições multifuncionais compreendendo ácidos concentrados para recuperação melhorada de petróleo e gás
JP2022541605A (ja) * 2019-07-24 2022-09-26 ソル － ゲル テクノロジーズ リミテッド 局所タピナロフ－ｅｇｆｒ阻害剤組成物による皮膚障害の治療
WO2021059283A1 (en) * 2019-09-26 2021-04-01 Sol-Gel Technologies Ltd. Treatment of cutaneous adverse effects caused by oncological therapy with topical tapinarof compositions
US20220331268A1 (en) * 2019-09-26 2022-10-20 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical combination compositions comprising tapinarof and an additional ahr activator
EP4054526A4 (en) * 2019-11-06 2023-05-24 Sol-Gel Technologies Ltd. METHOD FOR TREATMENT OF PALMOPLANTARIAL KERATODERMA
WO2021100051A1 (en) * 2019-11-24 2021-05-27 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical compositions comprising tapinarof and a pde4 inhibitor
GB202000167D0 (en) * 2020-01-07 2020-02-19 Cytovation As Composition for treatment of neoplastic lesions
US11154486B2 (en) 2020-02-14 2021-10-26 William M. Yarbrough Foundation Detergent compositions for washing urushiol and methods of treating urushiol induced contact dermatitis
US11191708B2 (en) * 2020-02-17 2021-12-07 William M. Yarbrough Foundation Sodium lauroyl sarcosinate containing detergent compositions
KR20230026497A (ko) * 2020-06-24 2023-02-24 더마반트 사이언시즈 게엠베하 국소 약제학적 조성물
CN115867267A (zh) * 2020-06-30 2023-03-28 德米拉公司 RORγt抑制剂和其局部用途
WO2022066803A1 (en) 2020-09-22 2022-03-31 Alphyn Biologics, Llc Topical croton lechleri compositions and their use in the treatment of a bacterial colonization or primary or secondary bacterial infection of an underlying skin disorder
MX2023005658A (es) * 2020-11-23 2023-09-07 Dermavant Sciences GmbH Formulaciones de gel, ungüento y espuma de tapinarof y metodos de uso.
EP4294518A4 (en) * 2021-02-17 2025-01-08 Dermavant Sciences GmbH VOMITING EFFECT OF TAPINAROF IN THE TREATMENT OF PLAQUE PSORIASIS, ATOPIC DERMATITIS OR RADIATION DERMATITIS
AU2022226676A1 (en) 2021-02-25 2023-09-28 Alphyn Biologics, Llc Composition for treatment of topical dermatological bacterial skin conditions
CN113797159A (zh) * 2021-10-22 2021-12-17 冠昊生物科技股份有限公司 一种本维莫德乳膏剂及其制备方法和用途
US20260069553A1 (en) * 2022-08-30 2026-03-12 Dermavant Sciences GmbH TAPINAROF AND ANALOGS THEREOF FOR USE IN TREATING AhR MEDIATED DISEASES
EP4629961A4 (en) * 2022-12-08 2026-03-25 Hairdao Payments Llc Topical compositions to treat and prevent hair loss and graying hair
WO2025031935A1 (en) 2023-08-04 2025-02-13 Sandoz Ag Crystalline forms of tapinarof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5111748A (en) 1974-07-16 1976-01-30 Taisho Pharmaceutical Co Ltd Suchirubenjudotaino seizoho
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
JPS58159410A (ja) 1982-03-18 1983-09-21 Mitsubishi Chem Ind Ltd 抗炎症剤
JPH0832638B2 (ja) * 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5008100A (en) 1989-08-11 1991-04-16 Elizabeth Arden Co., Division Of Conopco, Inc. Oil-in-water emulsions containing polyethylene
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
AU7513994A (en) 1993-07-27 1995-02-28 Agro-Biotech Corporation Novel fungicidal properties of metabolites, culture broth, stilbene derivatives and indole derivatives produced by the bacteria (xenorhabdus) and (photorhabdus) spp.
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
JPH1072330A (ja) 1996-09-03 1998-03-17 Kansai Kouso Kk チロシナーゼ活性阻害剤及び化粧料
JPH1143436A (ja) * 1997-07-25 1999-02-16 Showa Denko Kk 末梢血流障害予防・治療剤
WO1999040887A1 (en) 1998-02-10 1999-08-19 Shiseido Company, Ltd. Oil-in-water type emulsified compositions
SE9800729L (sv) 1998-03-06 1999-09-07 Scotia Lipidteknik Ab Ny topikal formulering I
FR2777183B1 (fr) 1998-04-10 2001-03-02 Oreal Utilisation d'au moins un hydroxystilbene dans une composition destinee a favoriser la desquamation de la peau et composition le comprenant
WO1999059561A2 (en) 1998-05-18 1999-11-25 Hensley, Kenneth, L. Resveratrol inhibition of myeloperoxidase
DE19842730A1 (de) * 1998-09-18 2000-03-23 Beiersdorf Ag Emulgatorfreie feindisperse Systeme vom Typ Öl-in-Wasser und Wasser-in-Öl
FR2785284B1 (fr) 1998-11-02 2000-12-01 Galderma Res & Dev Analogues de la vitamine d
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US20020054895A1 (en) * 1999-07-23 2002-05-09 Alwyn Company, Inc. Allantoin-containing skin cream
CA2393297C (en) * 1999-12-06 2010-10-05 Welichem Biotech Inc. Polyhydroxystilbenes as antipsoriatic agents and protein kinase inhibitors
US7321050B2 (en) * 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
FR2811564B1 (fr) 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
CN100462354C (zh) 2001-01-18 2009-02-18 天济药业（深圳）有限公司 治疗免疫疾病的新的1,2-二苯基乙烯衍生物
EP1435894A4 (en) 2001-07-23 2005-07-06 Galileo Pharmaceuticals Inc CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS AND METHOD
RU2212763C2 (ru) * 2001-08-16 2003-09-20 Общество с ограниченной ответственностью "Подсолнечник Технологии" Система открытой оптической связи
WO2003077856A2 (en) * 2002-03-12 2003-09-25 Playtex Products, Inc. Lotion compositions
US20040202634A1 (en) * 2003-03-19 2004-10-14 L'oreal Composition useful for cosmetic or dermatological use containing a block copolymer
BRPI0508933A (pt) 2004-03-18 2007-08-14 Panacea Biotec Ltd composições para entrega tópica
US20060018861A1 (en) * 2004-07-23 2006-01-26 Minghua Chen Skin care composition
PT1809383E (pt) * 2004-10-19 2008-11-06 Boots Co Plc Composições cosméticas
US20060246098A1 (en) * 2005-03-16 2006-11-02 Srinivasa Rao Stable aqueous-based emulsion formulation comprising urea and salicylic acid and method of using same
KR20070057660A (ko) * 2005-12-01 2007-06-07 롬 앤드 하아스 컴패니 활성물을 안정시키기 위한 수성 폴리머 분산액
FR2898498B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
US20080206155A1 (en) * 2006-11-14 2008-08-28 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
EP1930499A1 (en) * 2006-12-08 2008-06-11 Cognis IP Management GmbH Tissue paper comprising a softening lotion
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
WO2009108762A2 (en) 2008-02-26 2009-09-03 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
JP2011518844A (ja) * 2008-04-25 2011-06-30 ナノバイオ コーポレーション 真菌、酵母および糸状菌感染症を治療するためのナノエマルション
JP2009291133A (ja) * 2008-06-05 2009-12-17 Snow Brand Milk Prod Co Ltd チーズ食品
AU2010217190B2 (en) * 2009-02-25 2012-10-25 Mayne Pharma Llc Topical foam composition
MX359879B (es) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
CN101822638A (zh) * 2009-12-01 2010-09-08 河北科技大学 二苯乙烯类化合物的纳米乳及其制备方法
US20130303495A1 (en) * 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
EP2542208A1 (en) * 2010-03-01 2013-01-09 Photocure ASA Cosmetic compositions
WO2012053007A1 (en) * 2010-10-21 2012-04-26 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment psoriasis
WO2012075319A2 (en) 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical cream compositions and methods of use
CN103930565B (zh) 2011-06-27 2017-06-30 高德美研究及发展公司 用于痤疮的新th17分化标志物及其用途
WO2013130535A1 (en) 2012-02-27 2013-09-06 Newgen Biopharma Corporation Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
CN102657610A (zh) 2012-05-11 2012-09-12 河北科技大学 3,5-二羟基-4-异丙基二苯乙烯微乳剂及其制备方法
CN102657602B (zh) 2012-05-22 2013-08-07 河北科技大学 3,5-二羟基-4-异丙基二苯乙烯壳聚糖凝胶剂及其制备方法
US9433680B2 (en) * 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
CN103315958B (zh) 2013-07-19 2014-10-29 河北科技大学 苯烯莫德纳米乳及其制备方法
WO2015085143A2 (en) 2013-12-06 2015-06-11 Stc.Unm Therapeutic agents for skin diseases and conditions
CN103992212B (zh) * 2014-05-29 2015-07-01 河北科技大学 顺式苯烯莫德的合成方法及顺式苯烯莫德的应用
US10376475B2 (en) 2014-12-12 2019-08-13 Dermavant Sciences GmbH Method of use
PL3297605T3 (pl) 2015-05-21 2022-07-11 Dermavant Sciences GmbH Kompozycje farmaceutyczne do stosowania miejscowego
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
CA3253169A1 (en) 2017-11-10 2025-10-27 Dermavant Sciences GmbH Process for preparing tapinarof

Also Published As

Publication number Publication date
CL2017002939A1 (es) 2018-03-16
IL282304A (en) 2021-05-31
CR20170528A (es) 2018-01-22
MX377629B (es) 2025-03-10
IL255203B (en) 2021-05-31
IL282304B1 (en) 2024-12-01
SMT202200224T1 (it) 2022-07-21
TWI705831B (zh) 2020-10-01
AU2016263161B2 (en) 2019-02-28
US20200101027A1 (en) 2020-04-02
US20160338973A1 (en) 2016-11-24
US10426743B2 (en) 2019-10-01
NZ736602A (en) 2024-10-25
UY36682A (es) 2016-12-30
BR112017024934A8 (pt) 2021-03-30
KR102669247B1 (ko) 2024-05-27
EA201792559A1 (ru) 2018-04-30
CN114042041A (zh) 2022-02-15
EA038624B1 (ru) 2021-09-24
ZA202007965B (en) 2022-12-21
SI3297605T1 (sl) 2022-08-31
US11458108B2 (en) 2022-10-04
BR112017024934A2 (pt) 2018-07-31
JP2021105027A (ja) 2021-07-26
WO2016185428A1 (en) 2016-11-24
CO2017011795A2 (es) 2018-02-28
US20190192446A1 (en) 2019-06-27
JP6863904B2 (ja) 2021-04-21
CN114042041B (zh) 2023-08-22
DK3297605T3 (da) 2022-06-07
MX2017014804A (es) 2018-02-15
UA125500C2 (uk) 2022-04-13
LT3297605T (lt) 2022-06-27
KR20180008490A (ko) 2018-01-24
PT3297605T (pt) 2022-05-30
CN107666902B (zh) 2021-09-21
HRP20220670T1 (hr) 2022-08-19
IL316851A (en) 2025-01-01
IL282304B2 (en) 2025-04-01
JP2024153800A (ja) 2024-10-29
PL3297605T3 (pl) 2022-07-11
US20190192445A1 (en) 2019-06-27
CA2986251A1 (en) 2016-11-24
HK1245074A1 (en) 2018-08-24
MX2020012595A (es) 2021-02-09
AU2019203627B2 (en) 2020-12-24
US11622945B2 (en) 2023-04-11
AU2019203627A1 (en) 2019-06-13
PE20180038A1 (es) 2018-01-09
TW201705940A (zh) 2017-02-16
US11612573B2 (en) 2023-03-28
CY1125318T1 (el) 2024-12-13
CN107666902A (zh) 2018-02-06
JP2018515561A (ja) 2018-06-14
AU2016263161A1 (en) 2017-11-16
US10195160B2 (en) 2019-02-05
SG11201708666RA (en) 2017-12-28
US20190151255A1 (en) 2019-05-23
JP7531658B2 (ja) 2024-08-09
IL255203A0 (en) 2017-12-31
EP4094752A1 (en) 2022-11-30
HUE059066T2 (hu) 2022-10-28
DOP2017000270A (es) 2017-12-15
RS63402B1 (sr) 2022-08-31
PH12017502092A1 (en) 2018-05-07
KR20240090730A (ko) 2024-06-21
EP3297605B1 (en) 2022-05-04
ES2914112T3 (es) 2022-06-07
EP3297605A1 (en) 2018-03-28
JP2023113829A (ja) 2023-08-16

Similar Documents

Publication Publication Date Title
JO3680B1 (ar) تركيبات صيدلانية موضعية
MX2020010907A (es) Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
BR102016017090B8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112018007947A2 (pt) uso de antagonistas de receptor ep4 para o tratamento de câncer de fígado associado a nash
MX2016011667A (es) Composiciones topicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
MX377919B (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
BR112021025701A2 (pt) Formulações e métodos de parasiticida de isoxazolina para tratar blefarite
ZA201904591B (en) Dexmedetomidine or medetomidine for use in treating separation anxiety in dogs
MX2021007161A (es) Agente que contiene acido ursodesoxicolico para tratar o prevenir la presbicia.
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol
MX2016008546A (es) Reduccion de queloides utilizando alantoina topica.
EA201792170A1 (ru) Производные индола
CL2018003268A1 (es) Ácidos carboxílicos para tratar/prevenir una enfermedad de la piel.
MX381515B (es) Composición farmacéutica que comprende nebivolol con tasa de disolución mejorada
MX2022015792A (es) Composiciones farmaceuticas topicas.
AR104699A1 (es) Composición farmacéutica tópica en emulsión y su uso para fabricar un medicamento
UA106472U (uk) Засіб для лікування дерматологічних захворювань